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Abstract
Mitral valve is a complex cardiac structure whose function depends on a proper synchro-
nization between each mitral valve apparatus. Considerable headway over the years has 
been made toward unraveling the theoretical aspects which unifies the dynamic func-
tion, structural properties, and pathobiological, pathophysiological performance of the 
cardiac valves. However, the aspect of mitral valve regurgitation caused by left atrial 
myxoma still remains a gray area in the field as the mechanism(s) behind the masked 
and/or the resultant mitral valve regurgitation in relation to left atrial myxoma remains 
elusive. Although the regurgitations in most scenarios are masked due to the presence of 
the myxoma itself, however, both invasive and noninvasive techniques employed cannot 
ascertain if the regurgitation seen is a resultant or concomitant factor as the underlying 
pathological processes causing mitral valve regurgitation play key roles in the disease 
pathology as it could be a series of activated measures caused by the myxoma itself. 
Elucidating the role left atrial myxoma plays in mitral valve regurgitation is critical to 
improving our understanding as the aim of this chapter is to discuss the current knowl-
edge of mitral valve regurgitation caused by left atrial myxoma in succinct with the 
elusive underlying pathological sequential cascade activated due to the presence of this 
neoplasm.
Keywords: myocardial infarction, myxoma, cardiac imaging techniques, 
echocardiography, embolism, mitral valve insufficiency, ischemic heart disease, 
degenerative heart disease, rheumatic heart disease, endocarditis
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1. Introduction
Atrial myxomas are primary cardiac tumors which are more than usually found accidentally 
on routine clinical investigations toward other medical ailments commonly growing on the 
interatrial septum with the fossa ovalis been the most common site. However, it might also 
arise from the posterior, anterior and left atrial appendage. Cardiac myxomas are generally a 
rear occurrence with benign left atrial myxomas (LAM) being the most predominant type after 
pathological examinations. They are however two known basic types of cardiac myxoma; firm 
smooth and gelatinous irregular fond-like surface type with LAM mainly exhibiting symp-
toms of left-sided heart failure such as dyspnea when lying flat or on either the left or right 
side, arrhythmias, pulmonary edema, and even paroxysmal nocturnal dyspnea as a result of 
obstruction of the mitral valve orifice. Other associating symptoms such as malaise, Reynaud 
phenomenon, clubbing localized swelling, weight loss without trying and joint pain present 
themselves as the myxoma increases in size. LAM could also be sessile or pedunculated with 
pedunculated myxomas being the more frequent of the two. LAM is a multifactorial entity as 
at its diagnosis could spell the presence of diverse underlying cardiac alignments apart from 
the classic Goodwin’s triad while been silent and/or masked as some could be asymptomatic or 
vague presenting with just fever and fatigue. Apart from the required prompt clinical investiga-
tive and the timely surgical interventions long-term morbidity and the permanent damage done 
by the constant pendulum-like movement to the mitral valve and its associated apparatus only 
but leads to possible irreversible progressive permanent cardiac damage and eventually sud-
den death. The resultant life-threatening complications encountered with LAM such as stroke, 
acute heart failure, arrhythmias and sudden death produces a thromboembolic- ischemic effect, 
valvular obstructions and other constitutional symptoms due to the silent masking nature of all 
LAM with vague symptoms which eventually lead to evident mitral valve insufficiencies [1].
Normal heart valve ensures a one-way blood flow all through the entire cardiac cycle with 
little interference and without any form of regurgitation. The semilunar valve [i.e., the aortic 
valve and the pulmonary valve] prevents backflow of blood into the ventricles during the 
diastolic phase, and the atrioventricular valves [mitral valve and tricuspid valve] prohibit 
reverse flow from the ventricle to the atrium during systole. The ability for the mitral valve 
to allow unrestricted forward flow largely depends on the structure, pliability, integrity, and 
mobility of the entire mitral valve apparatus. The longtime continuous left atrial pendulum-
like movement made by the LAM leads to disturbances in the function of the mitral valve 
which affects the entire cardiac function due to the failure of the valve to shut properly allow-
ing blood leak into the left atrium [regurgitation]. Significant changes done to the structure 
of the mitral valve such as annular dilatation results to an increase in mechanical stress over 
the entire valve structure sufficient enough to eventually produce Mitral valve regurgitation 
coupled with poor leaflet appositions or leaflet tears caused by the size of the myxoma as it 
constantly rebounds against the leaflets protruding into the left ventricle during systole as 
far as rupturing the tendinaes and over extending both the papillary muscle base initiating a 
vicious circle leading to mitral regurgitation. The resultant thromboembolic-ischemic effect of 
the papillary muscle caused by the multi-level blockage of the coronary artery plays a major 
role to the degree of mitral regurgitation seen [mild, moderate and sever] as the posterior 
aspect of the muscle receives blood supply from branches of the posterior descending artery, 
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taking its course from either the right or the circumflex coronary artery, depending on which 
is the dominant system as its much inclined to ischemia and necrosis produced by the occlu-
sion as compared to the anterior muscle which invariably secures its supply from either the 
branches of the circumflex artery and the septal left anterior descending artery which is less 
predisposed to ischemia and rupture caused by occlusion [1–3].
However, achieving a favorable better long-term results with any effective medical interven-
tions used in the management or treatment of mitral valve regurgitation produced by the 
resultant LAM is dependent on tackling the known types of processes responsible for mitral 
valve insufficiencies namely; rheumatic, ischemic, degenerative, infectious type [endocardi-
tis] and other related etiological factors such as calcific degeneration and collagen vascular 
disorders [2, 3]. Being the most common type of heart valve disorders with vast non-surgical 
and technical surgical methods used in treating mitral valve regurgitation, in-depth knowl-
edge to the known underlined process involved with mitral valve insufficiencies as a result 
of the consequent presence of the LAM is pivotal to achieving favorable long-term results 
as masked mitral valve regurgitation are always almost evident at diagnosis. It is therefore 
imperative for practicing cardiologist, pulmonologist, echo-cardiologist, cardiac surgeons 
and any other therapist and/or interventionist involved at the diagnostic work up to bear 
in mind the high possibility of a resultant mitral valve regurgitation produced by the atrial 
myxoma not also forgetting the associative know processes of mitral valve insufficiencies as 
all this could be masked by the presence of the myxoma itself limiting the chance for a proper 
intervention both therapeutically or surgically [1].
Be it as it may, this only adds to the existing questions in the field by practitioners regarding 
the pathology and physiology of LAM, the accompanied masked regurgitations, mitral valve 
prolapse and the underlying process involved with mitral valve insufficiencies along with the 
long-term prognosis. This scientific chapter aims to discuss the clinical implications of mitral 
valve regurgitation produced by LAM and the underlying processes involved with mitral 
valve insufficiencies.
2. Anatomy and physiology of mitral valve
The mitral valve is a complex anatomical structure made of an annulus, two leaflets, chordae 
tendineae, and the anterior and posterior papillary muscle. A synchronized movement of all 
the mitral valve apparatus is essential for the valve to function normally and their structural 
architecture enables them to cause a very low level of mechanical stress during the ventricu-
lar systole. Mitral valve insufficiencies occur due to structural defects or change affecting the 
normal architecture of the mitral valve apparatus as an effective function of the mitral valve 
solely depends on an efficient interaction of the whole mitral valve components including 
the left ventricle itself. The annulus is generally saddled in shape taking a kidney-like shape 
in systole and a round shape at diastole. However, it is anatomically divided into two dis-
tinct parts; an anterior and posterior portion with the former considered to be non-distensible 
found between two fibrous bodies while the latter accounts for about 2/3 of the mitral valve 
orifice and is considered to be easily prone to distention and dilatation with LAM and other 
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diseases affecting the mitral valve and the left heart [4, 5] (Figure 1). The two leaflets are also 
described as anterior and posterior with the anterior leaflet being wider with a shorter base 
while the posterior leaflet is narrower but with a much broader attachment. Three distinc-
tive scallops can be related to the posterior leaflet which is clinically distinctive and vital for 
proper mitral valve function in addition to the lateral and medial small commissural scallops 
namely; medial, middle and a lateral scallop with the middle scallop being the largest among 
the three (Figure 2) [6–8]. The rough zone of each leaflet comes in contact with that of its other 
counterpart as the total surface area of the leaflets is twice the total surface area of the mitral 
orifice itself giving a border surface area for leaflet coaptation during systole which in turn 
decreases the mechanical stress during a single cardiac circle. A decrease in mechanical stress 
is achieved with a synchronous contractive action produced by the papillary muscles during 
left ventricular systole which further leads to an adequate tethering of the mitral valve thereby 
ensuring that the rough zones of both leaflets are in a properly oriented vertical direction 
[9–11]. Any destructive or nondestructive change to the normal structure and architecture of 
the mitral valve apparatus caused by the resultant long-standing pendulum-like effect of the 
LAM such as annular dilatation [anterior and posterior], leaflet prolapse and/or retraction 
Figure 1. Schematic of the mitral annulus (black lines) (A): Time frames during the cardiac cycle and the volume change 
(gray lines) between both time frames (B): End systole and diastole (shaded gray). Saddle horn, the annular region 
closest to the aortic annulus.
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[anterior and posterior], chordae tendineae rupture or elongation and left ventricular abnor-
malities produced during the course of forward and backwards movement into the left ventri-
cle and back to the left atrium during systole and diastole results in mitral valve regurgitation 
[1, 4, 7, 11] .
3. Left atrial myxoma
Myxomas are the most prevalent primary cardiac tumors, with 80–85% found in the left 
atrium and an annual incidence of 0.5 per million commonly arising from the interatrial sep-
tum at the fossa ovalis to be precise but can, however, be found in any chamber of the heart 
and structures with timely surgical resection playing a vital role in its treatment and recovery. 
The “tumor plop” sound heard during auscultation is a pathognomonic sign as a result of the 
penetrating myxoma in and out of the left ventricle. Symptoms caused by LAM are intermit-
tent due to the occasional prolapse of the tumor through the atrioventricular valve and is also 
highly dependent on body position [1]. Cardiac myxomas usually occur between the third 
and sixth decades of an adult life taking a preference for the female sex with varying growth 
rate ranging from an absolute nonexistent growth to several millimeters per month. Familial 
inheritance, multicentricity, metastasis and inadequate excision increases the chance of car-
diac myxomas recurrences, increased morbidity and mortality rates leading to poor prognosis 
and further possibly irreversible cardiac conditions either by medicamentous therapy alone 
and/or in combination with other various surgical therapies. Planned scheduled follow-up 
is of great importance in ruling out the possibility of a tumor reoccurrence even after proper 
surgical therapy employed. Cardiac computed tomography, magnetic resonance imaging, 
Doppler assessment and a combination of both outpatient transthoracic echocardiography 
with intra and postoperative Transesophageal echocardiography are essential for identifying 
and grading the regurgitation which is essential for an adequate left atrial myxoma therapy 
as they help in making precise judgment and assessment of anatomical valvular structures, 
which are destroyed by the tumor and are easily missed as most regurgitation are masked by 
the sole presence of LAM, different loading conditions, body structure and position [1, 12–24].
Figure 2. Carpentier classification of a well-structured mitral valve leaflet. A: anterior; P: posterior.
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4. Pathology and physiopathology
The tendency of mitral valve regurgitation and the adjunct mitral valve prolapse develop-
ment is inevitably high with the presence of left atrial myxoma either before or after any 
interventions been made. The development of mitral valve prolapse is due to the persistent 
rebound pendulum-like motion of the left atrial myxoma on the valve apparatus during 
each cardiac circle. Echocardiographically, mitral valve prolapse is defined as the upward 
displacement of the mitral leaflets above 2 mm in diastole [silent] which is usually the case 
in patients presenting with LAM and above 3 mm [massive] which increases the regurgitant 
jets seen during the echocardiographic studies. However, mid-systolic click to late systolic 
murmur is pathognomonic auscultatory findings with mitral valve prolapse and underling 
regurgitation as it varies from being benign to a gradual or sudden advance stage depend-
ing on the prolapse and regurgitation grade either before or after therapeutic interventions 
with a significant morbidity and mortality rate. Fortunately, apart from the massive prolapse, 
bacterial endocarditis, thromboembolism, atrial fibrillations, myxomatous degenerations 
[Barlow’s disease] and rheumatic heart diseases play key roles in the resultant regurgitations 
caused by the left atrial myxoma. Histological features of mitral valve prolapse and regurgita-
tion are marked spongiosa proliferation, mucopolysaccharide acid replacement of the leaflet 
collagen causing thickening and leaflet redundancy. As a result of the changes made such as 
fibrotic leaflets, thinning and/or elongation of the chordae tendineae, proper valve coaptation 
during systole is rendered impossible due to the redundant and elongated leaflets coupled 
with overshooting into the left atrium and the disrupted tendineae which eventually ruptures 
leading to regurgitation.
5. Mitral regurgitation
Mitral valve regurgitation is a complex entity that could be caused by either one of the follow-
ing etiological factors such as; Marfan syndrome, acute rheumatic valve disease, degenerative 
[myxomatous], bacterial endocarditis, acute ischemia, papillary muscle rupture. However, 
mitral regurgitations are further categorized into two broad groups; acute and chronic [pri-
mary and secondary] mitral regurgitation and into two generally accepted classifications 
namely; Carpentier and Duran’s classification. Although identifying patients at risk, symp-
tomatic, asymptomatic and progressive stage of mitral valve regurgitation encountered in 
clinical settings have been made easier as compared to previous years with the most recent 
American Heart Association (AHA) and the American College of Cardiology (ACC) guide-
lines for patient management (see appendix A and B) [25].
Common clinical presentations encountered with LAM are either stenosis due to tumor pro-
lapse into mitral orifice or regurgitation due to tumor induced valve trauma. Furthermore, 
Mitral valve regurgitation associated with LAM is caused by ventricular and annular dilata-
tion, failure of leaflet coaptation and the direct damage of the leaflets and/or subvalvular 
apparatus due to the presence of the myxoma body itself as it transverses through the mitral 
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valve during each systolic and diastolic phase coupled with the myxoma body adherence to 
nearby structures of the mitral valve. The myxoma prolapse from the left atrium toward the 
left ventricle during the entire cardiac cycle eventually leads to mitral valve regurgitations of 
varying degrees, cause volume overload propagating both left atrial and left ventricular dila-
tation, annular dilatation due to the continuous mechanical stretch of the prolapsing tumor on 
the mitral annulus during each systolic and diastolic phase. However, the extent of valvular 
obstruction varies with body position as the presence of the myxoma body itself affects trans-
mitral blood flow and also tends to mask mild and moderate to severe mitral regurgitations 
due to the huge and floating myxoma body where large myxomas with long stalk produces a 
temporally complete obstruction of the mitral valve orifice resulting in syncope. The continu-
ous pendulum like or “wrecking ball” effect of the myxoma during each cardiac circle against 
the entirety of the mitral valve apparatus gives raise to regurgitations and its severity is highly 
dependent on the resultant effect of the myxoma body itself on the mitral valve [26–35]. The 
grade and severity of the regurgitation is highly dependent on the myxomas body size, stalk 
length [small, large, prolapsing and non- prolapsing] and to some varying degree body posi-
tion and the resultant changes of blood flow through the left heart [36].
5.1. Carpentier classification
As widely used and proposed by Carpentier, the anterior leaflet is indicated as A1, A2, and 
A3 but lacks a clear distinction between A1 and A2 and also between A2 and A3 because of its 
smooth surface. However, the analogous segments of the posterior leaflets are also indicated 
as P1 [anterolateral], P2 [middle], and P3 [posteromedial] and highly distinctive from each 
other [37]. Regurgitations occur when there is an annular dilatation and/or the free edge of one 
or both leaflets overrides the entire valve orifice during systole, chordae tendineae destruc-
tion or rupture, a papillary muscle tear or detachment, architectural left ventricular destruc-
tion and acute ischemia as a result of embolization due to the myxoma friability (Table 1). 
Regurgitations caused by LAM express themselves differently according to grades, degree, 
and size of the myxoma, different loading conditions, body structure, position and other 
masked underlying pathology so therefore, for a successfully understanding of mitral regur-
gitation caused by LAM, a clear knowledge of the components and anatomy of the mitral 
valve apparatus, possible functional alterations, analysis of the leaflet motion, and a proper 
grading system is essential for a better prognosis after management or repair [1] (Figure 2).
Type A The manifestation or appearance of mitral regurgitations is as a result of annular dilatation
Type B The manifestation or appearance of mitral regurgitations is as a result of .one of either leaflets overriding 
the annular plane during systole
Type C The manifestation or appearance of mitral regurgitations is as a result of restricted leaflet motion during 
both systole and diastole
Type D The manifestation or appearance of mitral regurgitations is as a result of restricted leaflet motion during 
systole only
Table 1. Carpentier’s classification of regurgitation of the mitral valve.
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• Type A is evident when there is annular dilatation only or in combination with leaflet per-
foration, as in endocarditis.
• Type B is caused by elongated chordae tendineae, as constantly seen in degenerative dis-
ease, or thinning of the papillary muscle, found in ischemic heart disease.
• Type C occurs when there is leaflet perforation or chordal rupture, as found in rheumatic 
diseases.
• Type D there is chordal rupture [rheumatic] or in combination with papillary muscle de-
tachment or displacement [ischemic].
5.2. Duran classification
Kumar et al. proposed their classifications based on the chordae tendineae insertion gotten 
from the two papillary muscle groups. Thus, the posterior leaflet scallops were designated as 
P1 [anterolateral] and P2 [posteromedial] and the larger middle scallop as posterior middle 
which was subdivided as PM1 and PM2 based on chordal origins while the anterior leaflets 
were divided into A1 with chordae crossing from the anterolateral papillary muscle and A2 
with chordae from the posteromedial papillary muscle [38] (Figure 3).
5.3. Acute mitral regurgitation
Acute mitral regurgitation occurs due to annular prolapse and the disruption of other differ-
ent structures of the mitral valve. The papillary muscle rupture or the detachment of the chor-
dae tendineae from the papillary muscles caused by the resultant myxoma pendulum-like 
movement during each cardiac circle causing disrupted valve motion and a rise in volume 
overload in combination with the high friable tendencies of LAM leading to embolization 
of the coronary arteries which eventually ends in myocardial infarction. The acute volume 
overload on the left ventricle combined with the regurgitant flow of blood into the left atrium 
during systole results in acute pulmonary congestion, dyspnea, and poor cardiac output [39].
5.4. Chronic mitral regurgitation
When categorizing chronic mitral regurgitation caused by left atrial myxoma, it is impor-
tant that the physician gives a proper distinction between chronic primary [degenerative] 
and chronic secondary [functional] mitral regurgitation as it clearly helps in identifying the 
underlying pathology in relation to the resultant effect caused by the myxoma itself.
• Chronic primary mitral regurgitation: This regurgitation is as a result of the myxomas de-
struction of a single valve component either in its function or architecture such as annular 
dilatation with regurgitant jets from the left ventricle to the left atrium. However, the pro-
longed and severe volume overload produced eventually causes irreversible myocardial 
damage, episodic periods of heart failure and finally sudden death
• Chronic secondary mitral regurgitation: In this type of regurgitation, the entire valve appara-
tus is somewhat normal but the regurgitant jets are caused by embolization of the coronary 
arteries on different levels from the fragments of the myxoma giving rise to myocardial 
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infarction precipitating severe left ventricular dysfunction and adverse remodeling which 
eventually causes papillary muscle detachment, tethering leaflets with associated annular 
dilatation preventing proper coaptation [40].
5.5. Ischemic heart disease
Ischemic mitral regurgitation is defined as a moderate to severe mitral leak precipitated by acute 
myocardial infarction caused by partial or total complete obstruction of one or more coronary 
arteries on a different level due to the myxoma friability which gives rise to various degree of 
mitral regurgitation by changing the geometry of the ventricle [spherical shape], distorted wall 
motion, lateral and apical deracinated papillary muscles or its deformation due to ischemia [41].
5.6. Degenerative heart disease
This type of regurgitation is perpetuated as little pieces of embolus from the myxoma gets 
stocked at the edges of the leaflets forming small nodules which prevents complete valve closure 
Figure 3. (A) Duran classification of a well-structured mitral valve leaflet, A: anterior; PM: posterior middle; P1: posterior 
lateral; P2: posterior medial. (B) Modified type A: anterior. P: posterior. PM: posterior middle [1: lateral. 2: Medial].
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leading to regurgitant backflow of blood into the left atrium during the course of each cardiac 
circle which over time leads to an enlarged left atrium and ventricle causing heart failure.
5.7. Rheumatic heart disease
Myxoma [Latin Greek word “muxa” for mucus] means a myxoid tumor of primitive connec-
tive tissue, a primary tumor affecting adult hearts commonly in the left atrium but can, how-
ever, be found in other locations. LAM inflammatory process gives rise to a rapid sequence of 
chordal thickening and retraction, commissural fusion and finally thickened leaflets [incom-
plete opening and closure of the leaflets] with an enlarged annulus which eventually leads 
to regurgitation. Though an uncommon relation to the underlying processes involved with 
LAM throughout its development until therapy, pathologist has confirmed postoperatively 
the pathological component of LAM to be a spindle tumor with mucus production histologi-
cally made up of fusiform, stellate, and or polygonal cells [42–45] and histologically associ-
ated with interleukin-6 [46].
5.8. Endocarditis
This type of regurgitation caused by LAM is rear as compared to other underlying resul-
tant pathological cause and may even be described by some physicians, surgeons, and inter-
ventionist as idiopathic due to its ambiguity. The vegetations formed involves series of the 
pathological process which is activated as a result of incomplete resection of the LAM in 
combination with natural human oral streptococcal inhabitants [Streptococcus sanguinis and/
or dysgalactiae] which gets into the bloodstream when opportunities present themselves such 
as during surgeries and colonize the heart valves especially the mitral valve. The result at first 
is noninfective, but as the collection of platelets, fibrin, microcolonies of microorganisms, and 
the scant inflammatory cells increases, it shifts to a subacute stage and finally to full-blown 
endocarditis due to bacterial accumulations as they lodge and aggregate at the site of the 
incomplete LAM resection [1, 47].
6. Conclusion and future directions
Being the most common primary cardiac neoplasm in adults, the present state of research 
on its set cause, Pathobiology, physiopathology, and pathophysiology are still elusive as 
clinical and research efforts are being channeled toward its morbidity, mortality and its pos-
sible reoccurrence after surgery. If resultant mitral regurgitations and long-term survival for 
patients is to be achieved as it’s the main goal in all neoplastic diseases, a proper understand-
ing of myxomas pathology and the probable underlying process that could occur before and 
after therapeutic and/or surgical interventions employed is highly essential to tackle the un 
resolving issue in the field. Management of this condition requires adequate therapeutical 
background knowledge of the various possible outcomes to allow for an early identifica-
tion of masked regurgitations caused by the LAM as a result of the probably altered valve 
motion or damaged valve apparatus in combination with the activated underlying processes 
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involved with a well-planned follow-up regimen as regurgitations in some cases might not 
be detected immediately after the intraoperative Transesophageal echocardiography is used 
to check if the myxoma was totally resected and the surgery satisfactory as it could be termed 
by the physician as a physiological residual regurgitation seen after such kind of surgery 
which could be detrimental in the long term. However, current clinical features and echocar-
diographic criteria’s are not sufficient enough to detect mitral regurgitations and probable 
underlying pathological conditions early to achieve an effective medical management and/
or surgical therapy.
The most challenging problem both surgeons and interventionist face is the doubtful nature 
surrounding possible resultant masked regurgitations with LAM as this could be residual fol-
lowing myxomas resection coupled with the underlying pathological factors aligned with this 
neoplasm as it propagates the destruction, perforation, elongation, thinning, tethering, thick-
ening, retraction, displacement and ischemic changes seen in mitral valve regurgitation and/
or prolapse. Bearing this in mind, at the slightest suspicion of hemodynamic and architectural 
change in mitral valve apparatus and ventricular geometry [remodeling] during medical man-
agement or surgical intervention, a thorough assessment of the mitral valve apparatus should 
be made using Transthoracic echocardiography [outpatient settings] and Transesophageal 
echocardiography [inpatient settings] in combination with the surgeons direct vision assess-
ment if surgery was the treatment of choice irrespective of the known diagnosis [myxoma] 
in order to rule out any possible concomitant pathology such as coronary embolization to 
achieve favorable long-term prognosis. Finally, future directions and approaches made by the 
various scientific communities should be directed toward identifying the key dynamic con-
cepts behind LAM biological, physiological and pathological components, clinical features 
and the echocardiographic criteria’s to be used in an early detection of mitral valve regurgita-
tion and the possible underlying pathological processes and/or complications that could pre-
cipitate silent mitral valve insufficiencies after medical management or surgical interventions 
as this will be an important achievement and a novel contribution to the field.
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List of abbreviated words
LAM left atrial myxoma
AHA American Heart Association
ACC American College of Cardiology
AppendixA. American Heart Association (AHA) and the American 
College of Cardiology (ACC) guidelines for the clinical management 
of patients with primary mitral regurgitations.
Class Class 
interpretation
Anatomy Valvular 
hemodynamics
Resultant consequence Symptoms
I At potential risk 
of mitral valve 
regurgitation 
development
*Valve prolapse [mild] 
but with adequate 
coaptation
*Valvular thickening 
accompanied with 
restriction of both 
leaflet
Absence of any visible 
regurgitant jets with 
Doppler and little vena 
contracta of 0.3 cm
Nonexistent and 
uneventful
None
II Gradual 
progressive 
mitral 
regurgitation
*Valve prolapse [severe] 
but with an adequate 
leaflet coaptation
*Loss of leaflet 
coaptation probably 
cause by [rheumatic 
valve]
*previous infective 
endocarditis
*Evident regurgitant 
jets <50%, vena 
contracta of <0.7 cm, 
with an effective 
regurgitant orifice 
of <0.40 cm2 and an 
angiographic grade 
between 1 and 2+
Adequate pulmonary 
pressure with a mild left 
atrial enlargement and 
normal left ventricle 
geometry.
None
III Tolerant 
asymptomatic 
mitral 
regurgitation
[Severe]
Same as the above 
with an addition of 
leaflets thickening with 
radiation heart disease
Same as the above but 
with an increase in: 
angiographic grade 
3–4+
Possible pulmonary 
hypertension, with a 
moderate to severe left 
atrial and ventricular 
enlargement
None
IV Symptomatic
Severe mitral 
regurgitation
Same as the above Same as the above Pulmonary 
hypertension is 
evidently present with a 
moderate to severe left 
atrial and ventricular 
enlargement
Decreased 
exercise 
tolerance, 
Exertional 
dyspnea
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AppendixB. American Heart Association (AHA) and the American 
College of Cardiology (ACC) guidelines for the clinical management 
of patients with secondary mitral regurgitations.
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Class Class 
interpretation
Anatomy Valvular 
hemodynamics
Resultant 
consequence
Symptoms
I At potential 
risk of 
mitral valve 
regurgitation 
development
Normal valve 
architecture in patients 
with cardiomyopathy 
or coronary diseases
Absence of any visible 
regurgitant jets with 
Doppler and little 
vena contracta of 
<0.30 cm
*Motion 
abnormalities with 
probably dilated 
left vertical with 
geometric change
*Myocardial 
disease
Evident symptoms 
are those of 
coronary ischemia 
which could be 
reversed with 
adequate therapy
II Gradual 
progressive 
mitral 
regurgitation
Loss of leaflets 
coaptation centrally 
combined with annular 
dilatation and motion 
abnormalities which 
are regional
ERO <30 cm2
and a regurgitant 
volume and fraction 
of <30–40 ml and <50% 
respectively
*Motion 
abnormalities with 
probably dilated 
left vertical with 
geometric change
*Myocardial 
disease
Evident symptoms 
are those of 
coronary ischemia 
which could be 
reversed with 
adequate therapy
III Tolerant 
asymptomatic 
mitral 
regurgitation
[Severe]
Loss of leaflets 
coaptation centrally 
combined with annular 
dilatation and motion 
abnormalities which 
are regional
ERO ≥30 cm2
and a regurgitant 
volume and fraction 
of
≥30–40 ml and ≥50% 
respectively
*Motion 
abnormalities with 
probably dilated 
left vertical with 
geometric change
*Myocardial 
disease
Evident symptoms 
are those of 
coronary ischemia 
which could be 
reversed with 
adequate therapy
IV Symptomatic
Severe mitral 
regurgitation
Loss of leaflets 
coaptation centrally 
combined with annular 
dilatation and motion 
abnormalities which 
are regional
*ERO 0.20 cm2
*Regurgitant volume 
30 mL
*Regurgitant fraction 
50%
*Motion 
abnormalities with 
probably dilated 
left vertical with 
geometric change
*Myocardial 
disease
* Evident symptoms 
are those of 
coronary ischemia 
which could be 
reversed with 
adequate therapy
*Exertional 
dyspnea
*Decreased exercises 
tolerance level
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